Fig. 2From: Synergistic co-administration of docetaxel and curcumin to chemoresistant cancer cells using PEGylated and RIPL peptide-conjugated nanostructured lipid carriersIn vitro release profile of docetaxel (DTX) and curcumin (CUR) from different DTX- or CUR-loaded formulations. Data represent the mean ± SD (n = 3)Back to article page